A Multi-Center, Open-Label, Phase II Study of Ipilimumab (MDX-010) Extended-Treatment Monotherapy or Follow-up for Patients Previously Enrolled in Ipilimumab (MDX-010) Protocols Revised Protocol 09, incorporating Administrative Letter 01, 02, Amendments 01, 04, 05, 06, 07, 08, 09, 10 and 11 (version 10.0, dated 06-Dec-12) + administrative letter 03 dated 31-Jan-12
Latest Information Update: 14 Jan 2020
At a glance
- Drugs Ipilimumab (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions
- Sponsors Bristol-Myers Squibb
- 08 May 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 28 Jan 2013 Planned End Date changed from 1 Apr 2012 to 1 Sep 2014 as reported by ClinicalTrials.gov.
- 19 Oct 2012 Planned number of patients changed from 207 to 248 as reported by European Clinical Trials Database.